iduronidase alpha-lectin fusion protein (BioStrategies)

N/A

Report date: 2025/03/20 14:49:49

Base Information

Drug Nameiduronidase alpha-lectin fusion protein (BioStrategies)
Drug Alias NameMPS IIIa (Biostrategies)plant-derived lysosomal enzyme (BioStrategies)plant-based enzyme replacement therapy (BioStrategies LC)
ClassificationBiologics > Protein drugs > EnzymeBiologics > Protein drugs > Recombinant protein > Fusion proteinNatural product/Extract
Mechanisms of ActionAlpha-L-iduronidase stimulantsSGSH gene transference
TargetsN-sulphoglucosamine sulphohydrolaseAlpha-L-iduronidase
Therapy Area/IndicationsLysosomal Storage DiseasesMucopolysaccharidosis IIIMucopolysaccharidosis I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBioStrategies LC
China Registration ClassN/A

Develop Information

Active CompaniesBioStrategies LC
Inactive CompaniesN/A
Active IndicationsLysosomal Storage DiseasesMucopolysaccharidosis IIIMucopolysaccharidosis I
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A